{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T22:33:27Z","timestamp":1762900407262,"version":"build-2065373602"},"reference-count":64,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100007579","name":"Auburn University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007579","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","japha.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Pharmacists Association"],"published-print":{"date-parts":[[2023,5]]},"DOI":"10.1016\/j.japh.2023.02.006","type":"journal-article","created":{"date-parts":[[2023,2,10]],"date-time":"2023-02-10T17:30:38Z","timestamp":1676050238000},"page":"709-719","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Comparative safety of generic versus brand calcineurin inhibitors in solid organ transplant patients: A systematic review and meta-analysis"],"prefix":"10.1016","volume":"63","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0417-1988","authenticated-orcid":false,"given":"Kaniz Afroz","family":"Tanni","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4624-9963","authenticated-orcid":false,"given":"Jingjing","family":"Qian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.japh.2023.02.006_bib1","series-title":"Kidney Transplantation\u2013Principles and Practice","first-page":"231","article-title":"Calcineurin inhibitors","author":"Mejia","year":"2014"},{"issue":"7","key":"10.1016\/j.japh.2023.02.006_bib2","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1007\/s00467-017-3735-z","article-title":"Generic immunosuppressants","volume":"33","author":"Medeiros","year":"2018","journal-title":"Pediatr Nephrol"},{"issue":"3","key":"10.1016\/j.japh.2023.02.006_bib5","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1097\/FTD.0000000000000640","article-title":"Therapeutic drug monitoring of tacrolimus-personalized therapy: second consensus report","volume":"41","author":"Brunet","year":"2019","journal-title":"Ther Drug Monit"},{"issue":"2","key":"10.1016\/j.japh.2023.02.006_bib6","doi-asserted-by":"crossref","first-page":"S396","DOI":"10.1016\/j.transproceed.2004.01.013","article-title":"Therapeutic drug monitoring of cyclosporine","volume":"36","author":"Jorga","year":"2004","journal-title":"Transplant Proc"},{"issue":"5","key":"10.1016\/j.japh.2023.02.006_bib7","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1136\/ejhpharm-2012-000258","article-title":"Equivalence and interchangeability of narrow therapeutic index drugs in organ transplantation","volume":"20","author":"Johnston","year":"2013","journal-title":"Eur J Hosp Pharm"},{"issue":"5","key":"10.1016\/j.japh.2023.02.006_bib8","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1586\/ecp.12.49","article-title":"The adverse pharmacology of calcineurin inhibitors and their impact on hepatitis C recurrence after liver transplantation: implications for clinical practice","volume":"5","author":"Garcia-Saenz-de-Sicilia","year":"2012","journal-title":"Expert Rev Clin Pharmacol"},{"issue":"2","key":"10.1016\/j.japh.2023.02.006_bib9","doi-asserted-by":"crossref","first-page":"481","DOI":"10.2215\/CJN.04800908","article-title":"Calcineurin inhibitor nephrotoxicity","volume":"4","author":"Naesens","year":"2009","journal-title":"Clin J Am Soc Nephrol"},{"issue":"3","key":"10.1016\/j.japh.2023.02.006_bib10","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1159\/000449020","article-title":"Bioavailability, efficacy and safety of generic immunosuppressive drugs for kidney transplantation: a systematic review and meta-analysis","volume":"44","author":"Tsipotis","year":"2016","journal-title":"Am J Nephrol"},{"key":"10.1016\/j.japh.2023.02.006_bib11","doi-asserted-by":"crossref","first-page":"h3163","DOI":"10.1136\/bmj.h3163","article-title":"Generic immunosuppression in solid organ transplantation: systematic review and meta-analysis","volume":"350","author":"Molnar","year":"2015","journal-title":"BMJ"},{"issue":"4","key":"10.1016\/j.japh.2023.02.006_bib12","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1111\/tri.13581","article-title":"Immunosuppression with generic tacrolimus in liver and kidney transplantation-systematic review and meta-analysis on biopsy-proven acute rejection and bioequivalence","volume":"33","author":"Kahn","year":"2020","journal-title":"Transpl Int"},{"key":"10.1016\/j.japh.2023.02.006_bib13","doi-asserted-by":"crossref","first-page":"b2535","DOI":"10.1136\/bmj.b2535","article-title":"Preferred Reporting Items for Systematic Reviews and Meta-Analyses: the PRISMA statement","volume":"339","author":"Moher","year":"2009","journal-title":"BMJ"},{"issue":"1","key":"10.1016\/j.japh.2023.02.006_bib14","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1177\/1094428106296638","article-title":"Methodology for dealing with duplicate study effects in a meta-analysis","volume":"11","author":"Wood","year":"2008","journal-title":"Organ Res Methods"},{"issue":"19","key":"10.1016\/j.japh.2023.02.006_bib15","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.2174\/0929867323666160115130241","article-title":"Biochemical markers of renal function","volume":"23","author":"Krstic","year":"2016","journal-title":"Curr Med Chem"},{"key":"10.1016\/j.japh.2023.02.006_bib18","doi-asserted-by":"crossref","first-page":"d5928","DOI":"10.1136\/bmj.d5928","article-title":"The Cochrane Collaboration\u2019s tool for assessing risk of bias in randomised trials","volume":"343","author":"Higgins","year":"2011","journal-title":"BMJ"},{"issue":"4","key":"10.1016\/j.japh.2023.02.006_bib19","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0120519","article-title":"The method quality of cross-over studies involved in Cochrane Systematic Reviews","volume":"10","author":"Ding","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.japh.2023.02.006_bib21","unstructured":"Douglas Altman DA, Birks J, Borenstein M, et\u00a0al. Chapter 10. Analysing data and undertaking meta-analyses. In: Jonathan J, Deeks JPH, Altman DG, eds. Cochrane Handbook for Systematic Reviews of Interventions."},{"issue":"6","key":"10.1016\/j.japh.2023.02.006_bib23","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1177\/0962280216669183","article-title":"Optimally estimating the sample mean from the sample size, median, mid-range, and\/or mid-quartile range","volume":"27","author":"Luo","year":"2018","journal-title":"Stat Methods Med Res"},{"issue":"7","key":"10.1016\/j.japh.2023.02.006_bib24","doi-asserted-by":"crossref","first-page":"2252","DOI":"10.1016\/j.transproceed.2008.06.043","article-title":"Therapeutic equivalence and mg:mg switch ability of a generic cyclosporine microemulsion formulation (Sigmasporin Microral) in stable renal transplant patients maintained on Sandimmun Neoral","volume":"40","author":"Al Wakeel","year":"2008","journal-title":"Transplant Proc"},{"issue":"3","key":"10.1016\/j.japh.2023.02.006_bib25","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1159\/000453671","article-title":"Conversion from brand-name neoral to the generic Ciqorin in stable renal transplant recipients","volume":"135","author":"Cortinovis","year":"2017","journal-title":"Nephron"},{"issue":"2","key":"10.1016\/j.japh.2023.02.006_bib26","doi-asserted-by":"crossref","first-page":"130","DOI":"10.4103\/0970-1591.32062","article-title":"Clinical evaluation of efficacy and safety of cyclosporine (Imusporin) in renal transplant patients with stable graft function maintained on neoral or bioral","volume":"23","author":"Jha","year":"2007","journal-title":"Indian J Urol"},{"issue":"3","key":"10.1016\/j.japh.2023.02.006_bib27","first-page":"426","article-title":"Safe conversion to Cicloral, a generic cylosporine, in both stable and de novo renal transplant recipients","volume":"21","author":"Kahn","year":"2010","journal-title":"Saudi J Kidney Dis Transplant"},{"key":"10.1016\/j.japh.2023.02.006_bib28","first-page":"08","article-title":"One-year multicenter double-blind randomized clinical Trial on the efficacy and safety of generic cyclosporine (Iminoral) in de novo kidney transplant recipients","volume":"08","author":"Khatami","year":"2013","journal-title":"Exp Clin Transplant Off J Middle East Soc Organ Transplant"},{"key":"10.1016\/j.japh.2023.02.006_bib29","first-page":"1421","article-title":"Conversion to generic cyclosporine A in stable chronic patients after heart transplantation [Comparative Study]","volume":"7","author":"Kraeuter","year":"2013","journal-title":"Drug Des Dev Ther"},{"issue":"3","key":"10.1016\/j.japh.2023.02.006_bib30","first-page":"1318","article-title":"Cyclosporine pharmacokinetics in stable renal transplant patients: effect of formulation Sandimmun versus Consupren versus Neoral","volume":"28","author":"Masri","year":"1996","journal-title":"Transplant Proc"},{"issue":"1","key":"10.1016\/j.japh.2023.02.006_bib31","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.transproceed.2011.12.002","article-title":"Safety and efficacy of generic cyclosporine arpimune in Filipino low-risk primary kidney transplant recipients","volume":"44","author":"Pamugas","year":"2012","journal-title":"Transplant Proc"},{"issue":"3","key":"10.1016\/j.japh.2023.02.006_bib32","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1111\/j.1399-0012.2005.00483.x","article-title":"The clinical impact of 1:1 conversion from Neoral to a generic cyclosporine (Gengraf) in renal transplant recipients with stable graft function","volume":"20","author":"Qazi","year":"2006","journal-title":"Clin Transplant"},{"issue":"4","key":"10.1016\/j.japh.2023.02.006_bib33","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1007\/s11096-014-9959-0","article-title":"Therapeutic monitoring of pediatric renal transplant patients with conversion to generic cyclosporin","volume":"36","author":"Riva","year":"2014","journal-title":"Int J Clin Pharm"},{"issue":"7","key":"10.1016\/j.japh.2023.02.006_bib34","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.1016\/j.transproceed.2006.07.004","article-title":"Comparison of generic cyclosporine microemulsion versus neoral in de novo renal transplant recipients managed by 2-hour postdose monitoring","volume":"38","author":"Sharma","year":"2006","journal-title":"Transplant Proc"},{"issue":"7","key":"10.1016\/j.japh.2023.02.006_bib35","doi-asserted-by":"crossref","first-page":"3533","DOI":"10.1016\/S0041-1345(98)01125-7","article-title":"A\u00a0one-year comparative study of Neoral vs Consupren in de novo renal transplant patients","volume":"30","author":"Stephan","year":"1998","journal-title":"Transplant Proc"},{"issue":"6","key":"10.1016\/j.japh.2023.02.006_bib36","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1111\/j.1440-1797.2004.00335.x","article-title":"Switchover to generic cyclosporine in stable renal transplant recipients: a single unit experience","volume":"9","author":"Talaulikar","year":"2004","journal-title":"Nephrology"},{"key":"10.1016\/j.japh.2023.02.006_bib37","doi-asserted-by":"crossref","first-page":"S12","DOI":"10.1038\/ki.2009.506","article-title":"Interchangeability of ciclosporin formulations in stable adult renal transplant recipients: comparison of Equoral and Neoral capsules in an international, multicenter, randomized, open-label trial","volume":"115","author":"Vitko","year":"2010","journal-title":"Kidney Int Suppl"},{"issue":"11","key":"10.1016\/j.japh.2023.02.006_bib38","doi-asserted-by":"crossref","first-page":"2780","DOI":"10.1097\/TP.0000000000001843","article-title":"Pharmacokinetics and clinical outcomes of generic tacrolimus (Hexal) versus branded tacrolimus in de novo kidney transplant patients: a multicenter, randomized trial","volume":"101","author":"Arns","year":"2017","journal-title":"Transplantation"},{"issue":"1","key":"10.1016\/j.japh.2023.02.006_bib39","first-page":"113","article-title":"A\u00a01-year Comparison of Generic tacrolimus (Tacni\u00ae) and Prograf\u00ae in Renal Transplant Patients: a Retrospective Matched Group Analysis","volume":"02","author":"Lindner","year":"2017","journal-title":"J\u00a0Clin Exp Transplant"},{"key":"10.1016\/j.japh.2023.02.006_bib40","doi-asserted-by":"crossref","first-page":"295","DOI":"10.2147\/DDDT.S149906","article-title":"Comparison of the long-term efficacy and safety of generic tacrolimus, Tacrobell, with Prograf in liver transplant recipients","volume":"12","author":"Choi","year":"2018","journal-title":"Drug Des Dev Ther"},{"issue":"1","key":"10.1016\/j.japh.2023.02.006_bib41","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1093\/ckj\/sfs154","article-title":"A\u00a0single-centre comparison of the clinical outcomes at 6 months of renal transplant recipients administered Adoport\u00ae or Prograf\u00ae preparations of tacrolimus","volume":"6","author":"Connor","year":"2013","journal-title":"Clin Kidney J"},{"issue":"12","key":"10.1016\/j.japh.2023.02.006_bib42","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1111\/ctr.12455","article-title":"De novo use of generic tacrolimus in liver transplantation-a single center experience with one-yr follow-up","volume":"28","author":"Dannhorn","year":"2014","journal-title":"Clin Transplant"},{"issue":"8","key":"10.1016\/j.japh.2023.02.006_bib43","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1111\/petr.12608","article-title":"Transition from brand to generic tacrolimus is associated with a decrease in trough blood concentration in pediatric heart transplant recipients","volume":"19","author":"Duong","year":"2015","journal-title":"Pediatr Transplant"},{"key":"10.1016\/j.japh.2023.02.006_bib44","first-page":"1","article-title":"Switching stable kidney transplant recipients to a generic tacrolimus is feasible and safe, but it must be monitored","volume":"2017","author":"Gonz\u00e1lez","year":"2017","journal-title":"J\u00a0Transplant"},{"issue":"4","key":"10.1016\/j.japh.2023.02.006_bib45","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1016\/j.surg.2015.05.024","article-title":"Generics: are all immunosuppression agents created equally?","volume":"158","author":"Hauch","year":"2015","journal-title":"Surgery"},{"key":"10.1016\/j.japh.2023.02.006_bib46","doi-asserted-by":"crossref","first-page":"4431","DOI":"10.2147\/DDDT.S229114","article-title":"Generic tacrolimus (Tacrobell \u00ae) shows comparable outcomes to brand-name tacrolimus in the long-term period after adult deceased donor liver transplantation","volume":"13","author":"Kim","year":"2019","journal-title":"Drug Des Dev Ther"},{"issue":"6","key":"10.1016\/j.japh.2023.02.006_bib47","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1016\/j.transproceed.2015.05.031","article-title":"Outcomes of early conversion from Prograf to generic tacrolimus in adult living donor liver transplant recipients","volume":"47","author":"Kim","year":"2015","journal-title":"Transplant Proc"},{"issue":"8","key":"10.1016\/j.japh.2023.02.006_bib48","first-page":"484","article-title":"Clinical outcomes after conversion from brand-name tacrolimus (Prograf) to a generic formulation in renal transplant recipients: a retrospective cohort study","volume":"38","author":"Marfo","year":"2013","journal-title":"P\u00a0T"},{"issue":"4","key":"10.1016\/j.japh.2023.02.006_bib49","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1016\/j.transproceed.2015.03.030","article-title":"Impact of conversion from Advagraf to twice-daily generic tacrolimus in kidney transplant recipients: a single-center study","volume":"47","author":"Melo","year":"2015","journal-title":"Transplant Proc"},{"issue":"12","key":"10.1016\/j.japh.2023.02.006_bib50","doi-asserted-by":"crossref","first-page":"3110","DOI":"10.1093\/ndt\/gft300","article-title":"Therapeutic equivalence and pharmacokinetics of generic tacrolimus formulation in de novo kidney transplant patients","volume":"28","author":"Min","year":"2013","journal-title":"Nephrol Dial Transplant"},{"issue":"9","key":"10.1016\/j.japh.2023.02.006_bib51","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1111\/j.1600-6143.2011.03615.x","article-title":"The impact of conversion from Prograf to generic tacrolimus in liver and kidney transplant recipients with stable graft function","volume":"11","author":"Momper","year":"2011","journal-title":"Am J Transplant"},{"issue":"2","key":"10.1016\/j.japh.2023.02.006_bib52","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1093\/ckj\/sfu015","article-title":"Systematic conversion to generic tacrolimus in stable kidney transplant recipients","volume":"7","author":"Rosenborg","year":"2014","journal-title":"Clin Kidney J"},{"key":"10.1016\/j.japh.2023.02.006_bib53","doi-asserted-by":"crossref","first-page":"203","DOI":"10.2147\/DDDT.S118154","article-title":"Comparison of the long-term efficacy and safety of generic Tacrobell with original tacrolimus (Prograf) in kidney transplant recipients","volume":"11","author":"Son","year":"2017","journal-title":"Drug Des Dev Ther"},{"issue":"11","key":"10.1016\/j.japh.2023.02.006_bib54","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1002\/phar.1130","article-title":"Evaluation of clinical and safety outcomes associated with conversion from brand-name to generic tacrolimus in transplant recipients enrolled in an integrated health care system","volume":"32","author":"Spence","year":"2012","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.japh.2023.02.006_bib55","first-page":"6139","article-title":"Efficacy and safety of a conversion from the original tacrolimus and mycophenolate mofetil to the generics Tacpan and Mowel after liver transplantation","volume":"9","author":"Vollmar","year":"2015","journal-title":"Drug Des Dev Ther"},{"key":"10.1016\/j.japh.2023.02.006_bib56","unstructured":"Deeks JJ, Higgins JPT, Altman DG; on behalf of the Cochrane Statistical Methods Group. Chapter 10. Analysing data and undertaking meta-analyses. Cochrane Training. Available at: https:\/\/training.cochrane.org\/handbook\/current\/chapter-10. Accessed March 5, 2022."},{"issue":"6","key":"10.1016\/j.japh.2023.02.006_bib57","doi-asserted-by":"crossref","first-page":"461","DOI":"10.7326\/0003-4819-130-6-199903160-00002","article-title":"A\u00a0more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation","volume":"130","author":"Levey","year":"1999","journal-title":"Ann Intern Med"},{"issue":"25","key":"10.1016\/j.japh.2023.02.006_bib58","doi-asserted-by":"crossref","first-page":"2601","DOI":"10.1056\/NEJMra064928","article-title":"Infection in solid-organ transplant recipients","volume":"357","author":"Fishman","year":"2007","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"10.1016\/j.japh.2023.02.006_bib59","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1111\/ctr.12282","article-title":"Does the calcineurin inhibitor have influence on cytomegalovirus infection in heart transplantation?","volume":"28","author":"Rodr\u00edguez-Serrano","year":"2014","journal-title":"Clin Transplant"},{"issue":"3","key":"10.1016\/j.japh.2023.02.006_bib60","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1016\/j.transproceed.2018.02.046","article-title":"Cyclosporine versus tacrolimus: which calcineurin inhibitor has influence on cytomegalovirus infection in cardiac transplantation?","volume":"50","author":"Bond","year":"2018","journal-title":"Transplant Proc"},{"issue":"7","key":"10.1016\/j.japh.2023.02.006_bib61","doi-asserted-by":"crossref","first-page":"515","DOI":"10.6061\/clinics\/2015(07)09","article-title":"Cytomegalovirus infection in transplant recipients","volume":"70","author":"Azevedo","year":"2015","journal-title":"Clinics"},{"issue":"9","key":"10.1016\/j.japh.2023.02.006_bib62","doi-asserted-by":"crossref","first-page":"1992","DOI":"10.1111\/ajt.12850","article-title":"Proceedings from an International Consensus Meeting on posttransplantation diabetes mellitus: recommendations and future directions","volume":"14","author":"Sharif","year":"2014","journal-title":"Am J Transplant"},{"issue":"1","key":"10.1016\/j.japh.2023.02.006_bib63","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1210\/er.2015-1084","article-title":"Post-transplant diabetes mellitus: causes, treatment, and impact on outcomes","volume":"37","author":"Shivaswamy","year":"2016","journal-title":"Endocr Rev"},{"issue":"2","key":"10.1016\/j.japh.2023.02.006_bib64","doi-asserted-by":"crossref","first-page":"167","DOI":"10.33549\/physiolres.933332","article-title":"Pathophysiological mechanisms of calcineurin inhibitor-induced nephrotoxicity and arterial hypertension","volume":"66","author":"Ho\u0161kov\u00e1","year":"2017","journal-title":"Physiol Res"},{"issue":"3","key":"10.1016\/j.japh.2023.02.006_bib65","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1053\/j.ajkd.2010.03.026","article-title":"Comparative performance of the CKD Epidemiology Collaboration (CKD-EPI) and the Modification of Diet in Renal Disease (MDRD) Study equations for estimating GFR levels above 60 mL\/min\/1.73 m2","volume":"56","author":"Stevens","year":"2010","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.japh.2023.02.006_bib66","doi-asserted-by":"crossref","first-page":"c221","DOI":"10.1136\/bmj.c221","article-title":"Meta-analysis of individual participant data: rationale, conduct, and reporting","volume":"340","author":"Riley","year":"2010","journal-title":"BMJ"},{"issue":"Suppl 1","key":"10.1016\/j.japh.2023.02.006_bib67","doi-asserted-by":"crossref","first-page":"S110","DOI":"10.4103\/0976-500X.120972","article-title":"Safety and efficacy of generic drugs with respect to brand formulation","volume":"4","author":"Gallelli","year":"2013","journal-title":"J\u00a0Pharmacol Pharmacother"},{"issue":"3","key":"10.1016\/j.japh.2023.02.006_bib68","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1177\/1060028019881692","article-title":"Generic drugs not as safe as FDA wants you to believe","volume":"54","author":"White","year":"2020","journal-title":"Ann Pharmacother"},{"issue":"5","key":"10.1016\/j.japh.2023.02.006_bib69","first-page":"589","article-title":"Can we trust the quality of generic drugs?","volume":"26","author":"Eban","year":"2020","journal-title":"J\u00a0Manag Care Spec Pharm"},{"key":"10.1016\/j.japh.2023.02.006_bib70","doi-asserted-by":"crossref","first-page":"d8141","DOI":"10.1136\/bmj.d8141","article-title":"Impact of document type on reporting quality of clinical drug trials: a comparison of registry reports, clinical study reports, and journal publications","volume":"344","author":"Wieseler","year":"2012","journal-title":"BMJ"}],"container-title":["Journal of the American Pharmacists Association"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1544319123000225?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1544319123000225?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T05:52:54Z","timestamp":1761544374000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1544319123000225"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5]]},"references-count":64,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,5]]}},"alternative-id":["S1544319123000225"],"URL":"https:\/\/doi.org\/10.1016\/j.japh.2023.02.006","relation":{},"ISSN":["1544-3191"],"issn-type":[{"type":"print","value":"1544-3191"}],"subject":[],"published":{"date-parts":[[2023,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comparative safety of generic versus brand calcineurin inhibitors in solid organ transplant patients: A systematic review and meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Pharmacists Association","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.japh.2023.02.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 American Pharmacists Association\u00ae. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}